Exercise-induced asthma by Constantinou, D
Asthma is a reversible airways disease, characterised by hyper-
responsiveness of the bronchial tree to a variety of stimulants.
These include, among others, allergens (such as house dust mite,
pollen, mould, and animal dander), viral infections, cigarette and
other smoke inhalation, cold air and exercise. 
Exercise-induced asthma (EIA) is reversible airway obstruction
that occurs during or soon after physical activity. The stimulus of
exertion leads to post-exertional bronchoconstriction.  EIA can
affect anyone at any level of exercise participation, from school-
children to Olympic-level international elite athletes. Eighty to
ninety per cent of known asthmatics will also have EIA and it is
found in 40% of individuals with allergic rhinitis, atopic dermati-
tis or eczema.  A number of individuals may have the condition
associated only with exercise.  The exact prevalence is difficult to
ascertain, but is estimated to be around 15%.  Frequently young
children and adolescents with EIA avoid physical activity
because of their symptoms.
In normal individuals following a bout of exercise early bron-
chodilation occurs due to catecholamine release. This does not
occur in patients with EIA — in fact bronchoconstriction occurs 
6 - 8 minutes after exercise.  The lung function continues to
decrease, with the peak effect about 15 minutes after exercise.
The lung functions will usually return to normal within 2 hours
after exercise.
The extent of EIA is exercise-intensity related. Usually exertion
above 75 - 80% of predicted maximum heart rate (predicted
maximum heart rate is calculated as 220 – age) will induce EIA.
The nature of physical activity may have an influence (Table I),
but the minute-ventilation parameter is essentially comparable
with the different sports or activities at which the stimulus for EIA
occurs.
There is a refractory period in which there is a blunted response
to a repeat bout of intense exercise within 2 hours after an initial
EIA response.  In this period, there is a weaker or absent bron-
chospasm response.  The refractory period can be used to the
advantage of athletes, if the athlete then competes following a
warm-up in this period.  The exact mechanism of the refractory
period is unknown, and perhaps could be related to bronchodila-
tory prostaglandin and catecholamine release.
PATHOPHYSIOLOGY OF EIA
The exact pathophysiology of EIA is unknown, but two theories
currently prevail.  The first is the water loss theory.  Increased
osmolarity of the bronchial mucosa is thought to result from the
typical tachypnoeic mouth breathing with exercise, without the
DEMITRI
CONSTANTINOU








Dr Constantinou is a Sports
Physician in Johannesburg.




Gauteng of the national
High Performance
Programme. He was Chief
Medical Officer of the SA
team to the Paralympics in
Sydney in 2000 and the All
Africa Games in 1999, and
Team Physician to the All
Africa Games in 1995 and
the Commonwealth Games
in 1998. His current inter-
ests include exercise in the
management of chronic dis-




MB ChB, BSc (Med) (Hons)
Sports Science, PhD, FACSM
Associate Professor
MRC/UCT Research Unit
for Sports Science and
Sports Medicine








Sports Science Institute of
South Africa
Cape Town
Wayne Derman is Past
President of the South African
Sports Medicine Association.
He was the Chief Medical
Officer of the National
Olympic Committee of South
Africa for the Sydney 2000
Olympic Games and has
been appointed as Chief
Medical Officer for Athens
2004. 
EXERCISE- INDUCED ASTHMA
126 CME March  2004  Vol.22  No.3
EXERCISE-INDUCED ASTHMA
Exercise-induced asthma (EIA) is reversible airway obstruction that occurs during or
soon after physical activity.
nasal warming, and loss of water from
the bronchial epithelium.  The effect is
a change in osmolarity, pH and tem-
perature, with the release of mediators
(including histamine, leukotrienes and
prostaglandins), leading to bron-
choconstriction.  
The other theory is the heat exchange
theory with increased ventilation lead-
ing to cooling of the airways.  The
effect post exertion is rebound warm-
ing that occurs with dilation of the ves-
sels in the bronchi.  This causes
mechanical narrowing of the airways,
and perhaps a mediator release phe-
nomenon leading to bronchospasm.
CLINICAL MANIFESTATIONS
OF EIA
Symptoms of EIA can include chest
tightness, shortness of breath, cough-
ing, wheezing during exercise,
fatigue, prolonged recovery after exer-
cise, poor exercise performance or
even chest pain during exercise.
Typically respiratory symptoms occur
within 5 - 10 minutes after starting a
vigorous exercise bout but maximal
bronchospasm may occur 3 - 15 min-
utes after the cessation of exercise.
There is usually spontaneous recovery
within 60 minutes after cessation of
exercise. 
Factors that can affect the usual timing
of onset and severity of EIA include: 
• environmental conditions such as
temperature (worse in cold temper-
atures), humidity, air pollution and
pollens
• underlying infections of the respira-
tory tract
• the type, duration or intensity of the
exercise
• lack of warm-up
• the time elapsed since the previous
exercise session. 
Activities such as running and cycling
which require high-intensity exercise
are most likely to cause EIA.
Generally, the colder the climate and
the more vigorous the exercise, the
more rapid and severe the bron-
chospasm.
DIAGNOSIS OF EIA
An important clinical differentiation
must be made between EIA and mild,
or more severe grades of chronic, per-
sistent asthma with an exercise-
induced component. This distinction is
important with regard to treatment,
because many patients with EIA
require only pre-exercise treatment,
whereas those with persistent asthma
require daily anti-inflammatory therapy
plus pre-exercise treatment.
It is also apparent that bronchial
hyperreactivity during exercise can
occur following an upper respiratory
tract infection and that the manage-
ment of this is of relatively short dura-
tion (6 weeks - 3 months) while asth-
ma usually requires long-term manage-
ment. 
Diagnosis therefore requires an accu-
rate history, physical examination, and
lung function testing at rest, during
and after exercise.
The clinical history should include
questions to determine the presence or
absence of the symptoms listed above. 
The physical examination focuses on
the respiratory system and ear, nose
and throat evaluation. Usually the
physical examination is non-contributo-
ry, but clinical signs of chronic asthma
(including wheezing), underlying respi-
ratory tract infection or symptomatic
allergy are important to exclude. An
algorithm for the clinical work-up of
the patient with suspected EIA is pre-
sented in Fig. 1.
A number of different methods can be
used to assess pulmonary function.
Peak flow meters are an inexpensive,
effective and widely available tool to
measure pulmonary function immedi-
ately before and after exercise at 1,
3, 5, 10 and 15 minutes. Peak flow
meters can also be effectively used to
monitor the response to therapy in the
field.
Spirometry and exercise testing form
the gold standard for the diagnosis of
EIA. Chronic asthma is differentiated
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• Winter sports (cold dry air) e.g. ice skating, ice hockey, cross-coun-
try snow skiing (relevant for vacationing South Africans, residents of
Northern hemisphere countries and competitive athletes in these
sports)









• Swimming in pools with low chlorine concentrations
• Golf
• Tennis
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from EIA alone by the absence of
symptoms and the FEV1 persistently
within the normal range at rest. When
the FEV1 is 85% of the predicted
value or less, the diagnosis may be
asthma or alternatively a chronic lung
disorder, and this should be investigat-
ed and treated according to estab-
lished guidelines (Guidelines for man-
agement of asthma in adults, 1990;
National Heart, Lung and Blood
Institute guidelines 1991). However, it
Fig. 1. Diagnostic and therapeutic algorithm in the work-up of the athlete with EIA. (EIA = exercise-induced asthma; ENT = ear
nose and throat; FEV1 = forced expiratory volume in one second; PFT = pulmonary function tests; Hx = history; Mx = manage-
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is important to note that an FEV1 with-
in the normal range does not exclude
chronic asthma and is in fact a feature
of mild intermittent asthma. If the FEV1
at rest is within the predicted range,
an exercise challenge should be
undertaken. The exercise test should
be undertaken in a cold laboratory
using either a treadmill or cycle
ergometer. The workload is rapidly
increased to reach > 80% max HR
within 2 - 3 minutes. The exercise
should be sustained for at least 5 min-
utes. Spirometry could be performed
at  1, 3, 5, 10 and 15 minutes after
exercise. If no symptoms occur with
laboratory testing the patient should
be tested before and after exercise
during participation in his or her own
sport. A histamine or methacholine
challenge may be undertaken in
sophisticated pulmonary laboratories.
This provides a more sensitive test for
bronchial hyperreactivity and if pres-
ent increases the probability that the
athlete’s symptoms represent EIA.
The spirometry criteria after exercise
for the diagnosis of EIA are listed in
Table II.
At a different occasion, the patient’s
response to inhaled bronchodilators
can be determined by measuring pul-
monary functions following administra-
tion of a bronchodilator. The improve-
ment in FEV1 after administration of a
bronchodilator should be at least 12%
(American Thoracic Society guidelines)
but preferably 15% (BTS guidelines).
Other investigations that may be
appropriate, depending on the history,
include chest X-rays, sinus X-rays, full
blood count, and serum IgE.
MANAGEMENT
Education on the nature of the condi-
tion is a very important aspect of man-
aging EIA.  Often this is directed not
only to the patient, but their parents,
coaches and peers.  This includes an
understanding of the condition, factors
that may influence it, how to try and
avoid acute attacks, management of
attacks, and how to use the inhalers
and/or their spacer devices correctly.
Non-pharmacological management
approaches are summarised in Table
III.  One needs also to take into
account allergens and other environ-
mental conditions when athletes are
travelling to other locations to com-
pete.  Some asthmatics deteriorate
when travelling, possibly based on
time zone changes and travel fatigue,
apart from the environmental factors,
which include humidity, heat and pol-
lution.  Patients should have sufficient
medication with them to last the dura-
tion of the journey.
A low salt diet may have benefits in
some athletes’ lung functions.
Pharmacological management is sum-
marised in Tables IV and V.  The phar-
macological treatments include inhaled
bronchodilators, inhaled anti-inflamma-
tories (corticosteroids), inhaled mast
cell stabilisers and leukotriene modi-
fiers (receptor antagonists and 
5-lipoxygenase inhibitors). 
Inhaled corticosteroids would,
specifically in those with chronic asth-
ma, be used on a long-term basis and
assist in reducing airway responsive-
ness.  In patients with pure EIA, using
corticosteroids on a long-term basis
may have benefits in some, but not all
patients.  These may be used on a
trial basis when other modalities have
not had the desired response.
Intranasal corticosteroids are impor-
tant adjunct treatments for those with
EIA as well as chronic or seasonal
rhinitis.
Inhaled beta-adrenergic drugs are
either short- or long-acting.  These
increase the concentration of cAMP in
cells, affecting the smooth-muscle
Table II. Severity of EIA based on decrease of FEV1 and PEFR
post exertion
15 - 20% 20 - 30% > 30%
Mild EIA Moderate EIA Severe EIA
Table III. Non-pharmacological management of EIA
Management Mode of action
Maintaining aerobic fitness Can exercise at lower ventilatory 
rate for given workload
Perhaps reduced airway responsiveness
Adequate warm-up/pre To induce refractory period
competition exercise
Avoid exercise in excessively cold Reduced responsiveness of airways
and/or dry air
Avoid exercise/intense exercise Rhinitis, sinusitis, allergies indicate 
when related symptoms present hyper-responsive state in airways
Adequate warming down Avoids rebound warming and reduces 
oedema
Change of exercise/sport With severe symptoms, changing 
activities to sports less likely to induce
EIA
Wearing of face mask Reduces inhalation of pollutants and
irritants
Avoiding known allergens or Prevents allergic reactivity
irritants
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Table IV. Pre-exercise medication for EIA 
Recommended Onset of Duration of 
Medications Mode dosage action effects (hours)
Beta-2 agonists
Salbutenol Metered dose 2 puffs 15 min before Within 5 min 3 - 6 hr
inhaler (MDI), exercise for adults and
dry powder device children ≥ age 4
Terbutaline sulfate MDI 2 puffs every 4 - 6 hr for 5 - 30 min 3 - 6 hr
adults and children ≥ 12
Salmeterol MDI, dry powder 2 puffs ≥ 30 - 60 min before Within 20 min 12 hr 
device exercise or 12 hourly
Formoterol MDI, dry powder 2 puffs ≥ 30 - 60 min before Within 15 min 12 hr 
device exercise or 12-hourly
Mast-cell 
stabilisers
Cromolyn sodium MDI 2 puffs within 60 min of – 2 hr 
exercise for adults and 
children ≥ age 5
Nedocromil sodium MDI 2 puffs, qid for adults and May take up to 2 hr 
children ≥ age 6 1 week of use for 
full effect
Table V. Long-term medication for EIA 
Recommended Onset of Duration of 
Medications Mode dosage action effects (hours)
Inhaled 
corticosteroids
Beclomethasone MDI ≥ age 12, 2 puffs (84 µg) 1 or 2 days –  
dipropionate tid or qid; age 6 - 12, 1 or 2 
puffs (42 - 84 µg) tid or qid
Budesonide MDI Adults, 1 - 2 puffs bid; children 24 hours – 
≥ age 6, 1 puff bid
Fluticasone MDI ≥ age 12, 2 puffs 24 hours –   
propionate (88 - 440 µg) bid
Triamcinolone MDI Adults, 2 puffs (200 µg) 1 week – 
acetonide tid or qid; children age 6 - 12, 




Montelukast Tablet 10 mg daily for those ≥ age 3 - 4 hours Up to 24 hours
15; 5 mg daily for children 
age 6 - 14
Zafirlukast Tablet 20 mg bid for adults and 30 min 12 hours
children ≥ age 12
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Eighty to ninety per cent of
known asthmatics will also
have EIA and it is found in
40% of individuals with
allergic rhinitis, atopic der-
matitis or eczema.
Symptoms of EIA can
include chest tightness,
shortness of breath, cough-




or even chest pain during
exercise.
Activities such as running
and cycling which require
high-intensity exercise are
most likely to cause EIA.
contractions of the bronchioles.  They
essentially act as bronchodilators and
are very useful when used prior to
exercise.  There may also be anti-
inflammatory effects by reducing the
release of mediators by mast cells,
specifically in the long-acting beta-
agonists.
The short-acting beta-2-agonists should
be used 20 - 30 minutes before exer-
cise and not immediately prior to exer-
cise. It is apparent that frequent
repeated use of these agents without
the protective effect of inhaled corti-
costeroids might lead to a decreased
efficacy over time. The longer acting
drugs may have a slower onset of
action, but last for up to 12 hours,
and so should be used as a morning
or twice daily dose regimen and not
too soon before the onset of exercise
— a period of 4 hours before exercise
is a safe margin.  The long-acting
beta-agonists are clearly useful for
endurance athletes and children. 
It is advisable that all athletes with EIA
carry with them short-acting beta-
adrenergic inhalers for times where
symptoms may develop despite their
regular management.
Mast cell stabilisers are inhalers
that include nedocromil sodium and
sodium cromoglycate/cromolyn sodi-
um.  They appear to be less effective
than the beta-agonist, but where the
latter side- effects (palpitations, insom-
nia, tremors) are a problem, they can
be used.  They may also be used in
combination with the beta-agonists
when those are not as effective as
desired.  The mast cell stabilisers can
be used repeatedly and frequently in a
day, unlike the beta-agonists.
Leukotrienes can cause smooth-muscle
contraction.  Leukotriene modi-
fiers are being used in chronic asth-
ma sufferers, usually alone in mild
asthma, or in combination with other
drugs.  They are convenient, as oral
formulations, have few side-effects and
are long-acting.  They are useful in
EIA, when the symptoms are mild, but
often need to be used as adjunct ther-
apy to optimise control.
Theophylline, an oral asthma treat-
ment, is useful in chronic asthmatics
who may require this for their manage-
ment.  It has not been found to be
specifically beneficial in those with
pure EIA. 
Anticholinergic inhaler treatment,
both short- and long-acting, is not as
effective in EIA as it is in chronic
obstructive pulmonary disease.
Oral antihistamines are not specifi-
cally indicated for use in EIA, but are
useful as adjunct treatment in those
athletes who have atopia in addition
to their EIA.
Commonly a combination of therapies
is required to achieve optimum con-
trol.  Caution should prevail with pre-
scribing anti-inflammatory medications
and beta-adrenergic blockers, which
can cause bronchoconstriction.
MONITORING ATHLETES
After the athletes have been on a trial
of active medication, they should be
reassessed by means of repeat exer-
cise testing and spirometry and symp-
tom diary monitoring, to assess the
effect of the management.  Athletes
showing no or only minor response to
the treatment or when the diagnosis of
EIA is in doubt (e.g. signs and symp-
toms of EIA without abnormality
demonstrated on spirometry before or
after exercise) should be evaluated for
vocal cord dysfunction, exercise-
induced hyperventilation, or chronic
gastro-oesophageal reflux.
IMPORTANCE OF SCREENING
As EIA is generally underdiagnosed, it
is suggested that team physicians have
an increased index of suspicion of this
condition and include screening ques-
tions in their history taking. When
indicated, spirometry before and after
exercise should be conducted during
the pre-participation athlete evalua-
tion. EIA can be successfully diag-
nosed and managed, allowing athletes
with EIA to compete at the highest
level of sport.
EIA AND DOPING OFFENCES
The World Anti-Doping Agency
(WADA) has published the prohibited
substance list and anti-doping code.
This is a universal code, and has strict
rules and regulations pertaining to
doping control matters.  It is impera-
tive that prescribing treatment to any
patient is done so with the Code in
mind to avoid any positive drug tests
that the athlete may undergo.  This
pertains to any athlete at any level,
not only elite or highly competitive ath-
letes.  The relevant article related to
asthma medication states: 
• ‘Category S6: Beta-2 agonists. The
use of these inhalers requires
Therapeutic Use Exemption. See
below for details on this. 
• Category S9: Glucocorticosteroids.
These are prohibited in any form
and by any route. Therapeutic use
exemption needs to be applied for
in inhaler or intranasal use for asth-
matics.’
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Therapeutic use
International standards apply for the
process of granting therapeutic use
exemption (TUE), such as indicated
above for beta-agonist inhaler therapy
and inhaled or intranasal corticos-
teroids in asthmatics.  TUE is applied
for the use of inhaled beta-agonists
and non-systemic corticosteroids with
an abbreviated application form. The
National Anti-Doping Agency (South
African Institute for Drug Free Sport
(SAIDS)) has processes in place to
grant TUE, according to international
standards and formats.  This institute
can grant TUE for national athletics
and international level athletes who
are not in the top 50 in the world for
their particular sport. Elite internatinal
athletes who are within the top 50
have to apply to their sports federation
for TUE. All these results will be sub-
mitted to the WADA. Specific forms
supplied by the institute must be com-
pleted by the athlete together with a
medical report by a pulmonologist or
team physician and be submitted to
the SAIDS for granting of TUE.  This
will include lung function tests (pre-
and post exercise) and bronchodilator
therapy.  Any additional results, if
available, should also be submitted
(e.g. blood tests, skin prick allergy
tests, radiology).  An athlete may be
granted TUE by written notification,
which will also be submitted to
WADA. Athletes have leave to appeal
with WADA, should they not be grant-
ed TUE by the National Anti- Doping
Agency or their sports federation.
EIA can easily be missed or over-
looked, and when appropriately
assessed and managed affords ath-
letes the opportunity of performing at
their optimal level without compro-
mise.  Exercise-induced asthma needs
to be monitored to ensure adequate
control at all times.  Patients are
advised to monitor their symptoms and
peak flow readings, which can easily
be achieved by keeping a logbook,
and seek assistance when appropri-
ate.
Exercise-induced asthma (EIA) is found in about 80 - 90% of asthmatics
About 15% of athletes have EIA.
Common symptoms include coughing, wheezing, and dyspnoea during or after exercise.
Lung function test in conjunction with exercise challenge test imperative.
The condition can be adequately treated, which permits exercise without constraint.
The refractory period can be used to an athlete’s advantage in reducing competition symptoms.
Pre-exertional use of beta-agonists is the commonest mode of management.
Environmental factors must be taken into account and manipulated when possible.
Regular follow-up is often necessary.
Be aware of doping regulations and applications of therapeutic use exemption.
IN A NUTSHELL
Further Reading
Holzer K, Brukner P, Douglass J. Evidence-based management of exercise-induced asthma. Curr Sports Med Rep 2003; 1(2): 86-92.
Rundell KW, Wilber RL, Szmedra L, Jenkinson DM, Mayers LB, Im J. Exercise induced asthma screening of elite athletes: field versus laboratory
exer
cise challenge. Med Sci Sports Exerc 2002; 32(2): 309-316.
Rundell KW, Jenkinson D M. Exercise-induced bronchospasm in the elite athlete. Sports Med, 2002; 32(9): 583-600.
Tan RA, Spectro SL. Exercise-induced asthma: diagnosis and management. Ann Allergy Asthma Immunol 2002; 89(3): 226-235: 235-237, 297.
World Anti-Doping Agency. Prohibited List and Anti-Doping Code, 2004. www.wada.org.
